# ALX Oncology Holdings Inc

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/ALX Oncology Holdings Inc).

## Overview

ALX Oncology Holdings Inc is a clinical-stage biotechnology company developing immuno-oncology therapies for cancer, headquartered in South San Francisco, California. Its pipeline is centered on evorpacept (ALX148), a CD47 blocker designed to enhance macrophage-mediated tumor cell clearance while aiming to avoid hematologic toxicities seen with other CD47 approaches. The company is also advancing ALX2004, an EGFR-targeted antibody-drug conjugate (ADC) built from an in-house linker-payload platform, which entered first-in-human Phase 1 dosing in 2025. ALX Oncology has no products approved for marketing and has not generated revenue from product sales, with operations focused on R&D, clinical trials, and manufacturing scale-up for clinical supply.

## Products & services

• Evorpacept (ALX148) CD47 blocker (clinical-stage)
• ASPEN-09-Breast Phase 2 combo trial (evorpacept)
• ALX2004 EGFR-targeted ADC (Phase 1)
• Proprietary ADC linker-payload platform (R&D)
• ALTA-002 (with Tallac) TRAAC program (Phase 1)
• Clinical development & trial operations (outsourced CMOs/CROs)

- **Evorpacept (CD47 blocker) program** (65%) — Clinical development of evorpacept across Phase 1/2 studies, including combination regimens with targeted antibodies and chemotherapy.
- **ALX2004 (EGFR ADC) program** (20%) — First-in-human clinical development of an EGFR-targeted ADC using an in-house antibody and proprietary linker-payload design.
- **Early pipeline & collaborations (e.g., ALTA-002)** (10%) — Earlier-stage programs including partnered assets such as ALTA-002 (TRAAC) combining a SIRPα antibody with a TLR9 agonist.
- **Platform and enabling capabilities** (5%) — R&D and CMC capabilities supporting antibody engineering, linker-payload development, and clinical supply manufacturing scale-up.

- Evorpacept (ALX148) CD47 blocker (clinical-stage)
- ASPEN-09-Breast Phase 2 combo trial (evorpacept)
- ALX2004 EGFR-targeted ADC (Phase 1)
- Proprietary ADC linker-payload platform (R&D)
- ALTA-002 (with Tallac) TRAAC program (Phase 1)
- Clinical development & trial operations (outsourced CMOs/CROs)

## Customers

ALX Oncology is not yet commercial and therefore does not have traditional product customers; its near-term "customers" are clinical trial stakeholders and research partners that enable development. Clinical trial sites (academic medical centers and hospitals) and principal investigators administer investigational therapies under protocols, while patients enroll to access experimental treatments. The company also interacts with regulators (e.g., FDA) through IND submissions and trial oversight, which shapes development timelines and required evidence. If products are approved, the commercial customer chain would include oncologists and hospitals as prescribers/providers, specialty distributors, and third-party payors that determine reimbursement and access.

- **Clinical trial sites (hospitals/academic centers)** (primary) — Administer evorpacept and ALX2004 under protocols; critical for enrollment, safety monitoring, and data generation.
- **Investigator-sponsored trial (IST) partners** (secondary) — Academic institutions sponsor studies (e.g., UC San Diego) to explore new combinations/indications that can expand clinical evidence.
- **Future commercial providers and prescribers** (emerging) — Oncologists and infusion centers would adopt therapies based on efficacy/safety and guideline placement if approvals are obtained.
- **Future third-party payors** (emerging) — Public and private payors would influence access via coverage, prior authorization, and rebate/price reporting requirements post-approval.

- Clinical trial sites and investigators running Phase 1/2 studies
- Cancer patients enrolling in trials for investigational therapies
- Academic sponsors of investigator-sponsored trials (e.g., UC San Diego)
- Contract research organizations supporting trial execution and data
- Regulators (FDA) influencing trial design and approval pathways
- Future: oncologists/hospitals and payors if products are approved

## Geography

ALX Oncology is headquartered in South San Francisco, California and operates primarily through U.S.-based clinical development and regulatory activities. The company’s disclosed regulatory milestones in the excerpts are U.S.-centric, including FDA IND filings and clearances for ALX2004 and ALTA-002. Clinical trials are multi-center and may include sites beyond the U.S., but the provided excerpts do not quantify international footprint or revenue by geography. Because the company has no product sales, geographic exposure is driven more by where trials are conducted and where third-party manufacturers and service providers operate than by commercial demand patterns.

- Headquarters in South San Francisco, California (U.S. operating base)
- FDA IND filings/clearances indicate U.S.-centered regulatory pathway
- Multi-center trials imply distributed site footprint (not quantified)
- No product revenue; geography driven by trial and vendor locations
- Potential future expansion tied to global trial strategy and approvals

## Strategy

The company’s strategy is to advance evorpacept as a next-generation CD47 checkpoint inhibitor positioned for combination use with established anti-cancer antibodies and chemotherapy, aiming to become a backbone therapy in immuno-oncology. A second pillar is building an ADC franchise, starting with ALX2004, leveraging an in-house linker-payload platform to create differentiated EGFR-targeted constructs. ALX Oncology also uses collaborations to broaden its pipeline, exemplified by the Tallac Therapeutics partnership on ALTA-002. Execution priorities include progressing clinical trials, achieving enrollment and readouts, and securing reliable third-party manufacturing for clinical supply and eventual commercial scale if approvals are obtained.

- **Progress evorpacept through Phase 2 combination studies** (short-term) — Clinical efficacy and safety data in defined tumor settings drive partnering, pivotal trial design, and eventual approval prospects.
- **Establish an ADC development engine around ALX2004** (medium-term) — A differentiated ADC platform can create multiple follow-on candidates and diversify dependence on a single asset.
- **Expand pipeline via collaborations and early programs** (medium-term) — Partnered programs can broaden immuno-oncology approaches while sharing scientific and development risk.

- Advance evorpacept in combination trials to prove clinical benefit
- Position CD47 blockade with improved hematologic tolerability profile
- Build an in-house ADC pipeline starting with ALX2004 (EGFR)
- Leverage partnerships (Tallac/ALTA-002) to expand modalities
- Scale manufacturing and manage CMO relationships for clinical supply
- Raise additional capital to fund multi-trial development plans

## Risks

ALX Oncology faces binary clinical development risk because its value is concentrated in investigational assets, particularly evorpacept, which has not completed a pivotal trial. The company expects continued losses and requires substantial additional capital, creating financing and dilution risk if markets are unfavorable. Competitive risk is high in immuno-oncology and ADCs, where new approvals can shift standards of care and undermine trial relevance or enrollment. Operationally, the company relies on third parties (CMOs/CROs) for manufacturing and trial execution, and disruptions at agencies such as the FDA can delay reviews and development timelines. If products reach market, compliance risk increases due to U.S. healthcare laws (Anti-Kickback, False Claims, Sunshine Act) and distribution, pricing, and rebate program requirements.

- **Substantial dependence on evorpacept (ALX148) clinical success** [critical] — The company is substantially dependent on its lead candidate, which remains in clinical development and has not completed a pivotal trial.
- **Ongoing losses and need to raise additional capital** [high] — The company has incurred significant net losses, expects continued losses, and will require substantial additional capital that may not be available on favorable terms.
- **Competitive displacement and changing standard of care** [high] — Newly approved therapeutics in immuno-oncology could change treatment paradigms, negatively impacting trial design and prospects for evorpacept and ALX2004.
- **Regulatory and agency operational disruptions** [medium] — Disruptions at the FDA or other agencies could hinder timely review and approval activities on which development depends.

- Dependence on evorpacept success; no pivotal-trial completion yet
- Need for additional capital; funding may be unavailable or dilutive
- Clinical trial failure, delays, or enrollment shortfalls
- Rapidly evolving immuno-oncology/ADC competition and shifting SOC
- Third-party CMO/CRO execution and clinical supply risks
- Regulatory delays (FDA capacity disruptions, review timelines)
- Future commercialization compliance (AKS, FCA, Sunshine Act, pricing)

## Accounting

As a clinical-stage company with no product revenue, reported results are driven primarily by R&D and G&A expense recognition and the timing of clinical and manufacturing activities. A critical judgment area is the estimation of clinical trial and contract manufacturing accruals with CMOs, which requires management to estimate services performed and patient enrollment progress at period end. Changes in assumptions (e.g., enrollment rates, services performed, vendor invoices timing) can shift R&D expense between quarters and affect comparability. Investors should also expect lumpy quarterly expense patterns tied to trial starts, dosing cadence, and manufacturing campaigns rather than seasonality in revenue.

- **Clinical and contract manufacturing accruals (CMOs)** — Affects reported R&D expense, accrued liabilities, and quarterly comparability

- Clinical and contract manufacturing accrual estimates drive R&D timing
- Accruals depend on patient enrollment and services performed by CMOs
- True-ups to vendor accruals can create quarter-to-quarter volatility
- No product revenue; P&L dominated by operating expense recognition
- Monitoring for changes in critical accounting estimates disclosures

---

*Last updated: 2026-08-11T04:46:17.657877+00:00*